Krefting, Frederik
Moelleken, Maurice
Hölsken, Stefanie
Placke, Jan-Malte
Eisenburger, Robin Tamara
Albrecht, Lea Jessica
Tasdogan, Alpaslan
Schadendorf, Dirk
Ugurel, Selma
Dissemond, Joachim
Sondermann, Wiebke http://orcid.org/0000-0002-3684-3523
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 16 November 2023
Accepted: 10 April 2024
First Online: 16 April 2024
Competing interests
: Frederik Krefting received travel support for participation in congresses and / or (speaker) honoraria from Novartis, Lilly, Almirall, and Boehringer Ingelheim outside of the present publication. Stefanie Hölsken declares no conflict of interest. Jan-Malte Placke served as consultant and/or has received honoraria from Bristol-Myers Squibb, Novartis, Sanofi, and received travel support from Bristol-Myers Squibb, Novartis, Pierre Fabre, and Therakos. Maurice Moelleken received travel support for participation in congresses and/or (speaker) honoraria from Adtec-health Care and Urgo. Robin Tamara Eisenburger declares no conflict of interest. Lea Jessica Albrecht received honoraria from Novartis, Sun-pharma and Bristol-Myers Squibb and travel support from Sunpharma, Takeda, and Sanofi, outside the submitted work. Alpaslan Tasdogan declares no conflict of interest. Dirk Schadendorf is a consultant/scientific advisor to Array, Pfizer, Novartis, Bristol-Myers Squibb, MSD, Sanofi-Aventis, Neracare, Immunocore, Replimune, Daiichi-Sanyo, Labcorp, InFlarX, AstraZeneca, OncoSec, Merck-EMD, Nektar, Philogen, Pierre-Fabre, and Sun Pharma. In addition, Dirk Schadendorf has received institutional funding for research grants from Merck, Amgen, Novartis, MSD, Array, and Roche. Selma Ugurel declares research support from Bristol Myers Squibb and Merck Serono; speakers and advisory board honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, and Novartis, and travel support from Bristol Myers Squibb, Merck Sharp & Dohme, and Pierre Fabre. Joachim Dissemond declares no conflict of interest. Wiebke Sondermann received travel support for participation in congresses and / or (speaker) honoraria as well as research grants from medi GmbH Bayreuth, Abbvie, Almirall, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, GSK, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme, and UCB outside of the present publication.